Trial Profile
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism; Venous thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAP
- 03 Feb 2022 Results assessing the efficacy and safety of low-dose apixaban for 30 months, after initial six months of full-dose treatment, published in the Journal of Thrombosis and Haemostasis
- 24 Jun 2018 Status changed from recruiting to completed.
- 07 Jun 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.